Business Wire

CA-ANDERSEN-GLOBAL

10.6.2022 12:17:06 CEST | Business Wire | Pressemeddelelse

Del
Andersen Global udvider sit fodaftryk i Norden gennem samarbejdsaftaler i Finland og Danmark

Andersen Global fortsætter sin ekspansion på det nordiske marked gennem samarbejdsaftaler med det danske advokatfirma Bachmann/Partners og det finske advokatfirma I&O Partners. Med udgangspunkt i de eksisterende samarbejdende virksomheder Hellström Law og Unum i Sverige og Braekhus i Norge, styrker disse tilføjelser organisationens omfattende og integrerede skattemæssige og juridiske dækning i regionen.

Med kontorer i København og Aarhus tilbyder Bachmann/Partners en bred vifte af tjenester, herunder skattestrid og rådgivning, moms, punktafgifter, strafferetlig skatteret, arve- og ejendomsplanlægning for private og familieejede virksomheder med stor formue, international skatte- og erhvervsret. Bachmann/Partners, som er anerkendt af The Legal 500 som en konkurrencedygtig virksomhed i regionen, blev grundlagt i 2016 af ledende partner Christian Bachmann og leverer tjenester til lokale og internationale kunder.

”Vi har gennem årene opbygget vores omdømme på baggrund af vores store kendskab til dansk erhvervsliv, især vores specialisering i alle skatteretlige forhold”, siger Christian. ”Vi ser frem til at arbejde sammen med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fastholder en konkurrencefordel på markedet og leverer omfattende løsninger til kunder globalt”.

I&O Partners blev grundlagt i 2015 og bistår kunder inden for områder som bank og finans, virksomhedsrådgivning, erhverv, tvistbilæggelse, ansættelse, fusioner og opkøb, IP-teknologi, omstrukturering og privat formue. Under ledelse af ledende partner Andrei Aganimov arbejder virksomhedens team på mere end 16 fagfolk tæt sammen med nationale og internationale virksomheder såvel som private kunder.

”Virksomheden er vokset ret hurtigt siden vores grundlæggelse for næsten syv år siden, og vores samarbejde med Andersen Global er næste skridt i vores vækst og udvikling”, siger Andrei. ”Vores samarbejde positionerer os til at udnytte den kollektive styrke i en global organisation, overgå kundernes forventninger og levere problemfri service”.

”Bachmann/Partners og I&O Partners deler et stærkt engagement i klassens bedste service og en passion for forvaltning og gennemsigtighed”, siger Andersen Globals bestyrelsesformand og CEO Mark Vorsatz. ”Deres teams vil være et stort aktiv til at imødekomme vores kunders voksende behov og vil arbejde synergistisk med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fortsætter med at udbygge vores kapacitet i Nordeuropa”.

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013 og Andersen Global har nu over 11.000 fagfolk globalt og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye